【注】：“≥”表示该化合物大于等于标示浓度，但饱和浓度未知。

溶剂体积

 浓度

  体外研究（细胞实验）：

  细胞类型（Cell types）：Mouse atrial myocyte line (HL-1)

  实验方法（Assay）：Atrial myocytes were treated with 50 ng/mL anisomycin with or without 2 µmol/L SP600125, or a corresponding amount of the DMSO solvent for 16 or 24 h followed by biochemical or optical   mapping studies.

  体内研究（动物模型）：

  动物模型（Animal Model）：Young (6 months) and aged (54 months) male New Zealand White rabbits

  实验方法（Assay）：LA effective refractory period (AERP) was measured using an S1-S2 pacing protocol and atrial arrhythmias (AT/AF) were induced using burst pacing in open-chest heartsin young rabbits with (n = 4)  or without (n = 5)anisomycin treatment (15 mg/kg, iv, four treatments over 9 days)and aged rabbits without anisomycin treatment (n = 6).

 体内研究（动物模型）：

 动物模型（Animal Model）：Male C57BL/6 mice (8-12 weeks old)

 配制方法（Formulation）：Anisomycin wasdiluted in salineand dissolved in 1 M HCl. The pH was adjusted to≈7 with 1 M NaOH.

 实验方法（Assay）：Mice received subcutaneous injections of 50 or 75 mg of anisomycin/kg of body weight or an equivalent volume of saline in the first experiment. Injections in all other experiments were 50 mg/kg of anisomycin or an equivalent volume of saline.

 体内研究（动物模型）：

 动物模型（Animal Model）：

 配制方法（Formulation）：Anisomycin was dissolved inDMSO to prepare a stock solution anddiluted inPBS before each administration.

 实验方法（Assay）：Anisomycin (30 mg/kg body weight)or vehicle was injected subcutaneously daily after optic nerve crush. To inhibit OPP incorporation, anisomycin (50 μg/ml) was injected intravitreally 1 hr before  and together with OPP administration.